Showing results (221-230 of 491) with videos related to

Sort By:
Pageof 50
The American Journal of Cardiology|August 6, 2002
Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE)Philippe Gabriel Steg, Robert J Goldberg, Joel M Gore, et al.
The American Journal of Cardiology|September 28, 2011
Usefulness of the admission electrocardiogram to predict long-term outcomes after non-ST-elevation acute coronary syndrome (from the FRISC II, ICTUS, and RITA-3 [FIR] Trials)Peter Damman, Lene Holmvang, Jan G P Tijssen, et al.
JACC. Cardiovascular Interventions|February 25, 2012
Timing of angiography with a routine invasive strategy and long-term outcomes in non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II (Fragmin and Fast Revascularization During Instability in Coronary Artery Disease), ICTUS (Invasive Versus Conservative Treatment in Unstable Coronary Syndromes), and RITA-3 (Intervention Versus Conservative Treatment Strategy in Patients With Unstable Angina or Non-ST Elevation Myocardial Infarction) TrialsPeter Damman, Nan van Geloven, Lars Wallentin, et al.
Heart (British Cardiac Society)|June 8, 2006
Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE)K A A Fox, F A Anderson, O H Dabbous, et al.
JAMA|December 15, 2005
Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery diseaseDavid A Morrow, James A de Lemos, Michael A Blazing, et al.
Archives of Cardiovascular Diseases|August 12, 2009
Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trialJean-Philippe Collet, Gilles Montalescot, Philippe Gabriel Steg, et al.
Trials|February 27, 2008
Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study)David C Crossman, Allison C Morton, Julian P Gunn, et al.
American Heart Journal|July 6, 2010
Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trialChee Tang Chin, Matthew T Roe, Keith A A Fox, et al.
Circulation|June 3, 2010
Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trialPeter B Berger, Deepak L Bhatt, Valentin Fuster, et al.
Open Heart|December 14, 2023
Country and health expenditure are major predictors of withholding anticoagulation in atrial fibrillation patients at high risk of strokeDeborah M Siegal, Frederik H Verbrugge, Anne-Celine Martin, et al.
Pageof 50